Kidney damage in patients with chf and obesity (local register data)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To study the effect of obesity on the clinical and laboratory status of patients with chf depending on polymorbidity and the variant of kidney damage. material and methods. The study included 176 patients with chf aged 69.48±13.24 years. patients were divided into 2 groups: the main - 78 patients with obesity I-III degree and the comparison group - 98 (normal or overweight). venous blood was taken from all patients on the 1st-3rd day of hospitalization in order to determine the levels of creatinine, ngal, cystatin c, nt-probnp, st2 and their content was assessed depending on the presence and severity of obesity, the variant of kidney damage, and polymorbidity. results. in the studied sample, 44.32% of patients had obesity of i-iii degrees. every 2nd patient was diagnosed with obesity of the 1st degree, and almost every 3rd patient was diagnosed with obesity of the 2nd degree. 43.59% of patients with obesity had сз-5 ckd prior to the present hospitalization. in 37.18% of patients with obesity, proteinuria was determined, mainly of subnephrotic level. aki was diagnosed in every 5th patient (23.29%), in patients with obesity mainly (63.16%) of 2-з stages. during hospitalization, 2.84% of patients died. all the deceased developed aki stage 2 or з in the background of сз-5 ckd. patients with aki had higher levels of all studied biomarkers (ngal, cystatin c, nt-probnp, st2). according to our data, the presence of obesity is associated with the risk of developing aki (OR=2.269, 95% ci o.04-129.799) and the severity of aki (0R=1.246, 95% CI 0.459-3.386), THE FREQUENCY OF HOSPITALIZATION due to the development of ADHF (0R = 1.52, 95% ci o.666- 3.472). Conclusion. Timely diagnosis and treatment of obesity will reduce the risk of aki and mortality, development and progression OF ckd.

Full Text

Restricted Access

About the authors

Zinaida Dmitrievna Mikhailova

GBUZ no «City Clinical Hospital No. 38»

Email: zinaida.mihailowa@yandex.ru
Doctor of Medical Sciences, Associate Professor, Consultant 603000 Nizhny Novgorod, st. Chernyshevsky, 22

Yuliya Vasil'evna Omarova

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of the Russian Federation

Email: sailor94mihailova@yandex.ru
Ph.D. students Department of Therapy and Cardiology 603950, Nizhny Novgorod, Minin and Pozharsky Sq., 10/1

References

  1. Вялкова А.А., Лебедева Е.Н., Красиков С.И. и др. Клиникопатогенетические аспекты повреждения почек при ожирении (обзор литературы). Нефрология. 2014;18(3):24-33
  2. Бобкова И.Н., Гуссаова С.С., Ставровская Е.В. Поражение почек при ожирении: варианты течения, механизмы развития. Терапия. 2019;5(6):87-93. doi: 10.18565/therapy.2019.6.87-93
  3. Smiyan S., Franchuk M., Komorovsky R. Obesity as a risk factor for kidney damage in patients with gout. East Eur. Sci. J. 2018;5(33):44-8.
  4. Kotsis V., Martinez F., Trakatelli C., Redon J. Impact of Obesity in Kidney Diseases. Nutrients. 2021;13(12):4482. doi: 10.3390/nu13124482.
  5. Wang M., Wang Z, Chen Y, Dong Y. Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs.Int. J. Mol. Sci. 2022;23(2):747. Doi: 10.3390/ ijms23020747.
  6. Клиническая лабораторная диагностика (методы и трактовка лабораторных исследований). Подред. В.С. Камышникова. 2-е изд. М., 2017. 720 с.
  7. Martin K.J. «Oxford Textbook of Clinical Nephrology». Ed. by S. Cameron, A.M. Davison, J.P. Grunfeld, D.Kerr, and Eberhard Ritz. Am. J. Kidney Dis. 1992;20:674.
  8. Fogazzi G.B., Passerini F., Ponticelli C., Ritz E. The urinary sediment: аn integrated view. Milano/Masson, 1993. 145 p. ISBN 10: 0412593009 ISBN 13: 9780412593000.
  9. Fogazzi G.B., Grignani S. Urine microscopic analysis: an art abandoned by nephrologists? Nephrol. Dial. Transplant. 1998;13(10):2485-87. doi: 10.1093/ndt/13.10.2485.
  10. Смирнов А.В., Румянцев А.Ш. Острое повреждение почек. Часть I. Нефрология. 2020;24(1):67-95. https://doi.org/10.36485/1561-6274-2020-24-1-67-95.
  11. Клинические рекомендации. Хроническая болезнь почек (Ассоциация нефрологов), 2021. 233 с.
  12. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Росс. кардиологический журнал. 2020;25(11):4083. doi: 10.15829/1560-4071-2020-4083.
  13. Клинические рекомендации. Ожирение (Российская ассоциация эндокринологов, Общество бариатрических хирургов), 2020 (17.02.2021). 31 с. (Утверждены Минздравом РФ)
  14. Дедов И.И., Шестакова М.В., Мельниченко Г.А. и др. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний». Ожирение и метаболизм. 2021;18(1):5-99. Doi: https://doi.org/10.14341/omet12714.
  15. Клинические рекомендации. Железодефицитная анемия. Национальное гематологическое общество. Национальное общество детских гематологов, онкологов. Одобрено Научно-практическим Советом Минздрава РФ. 2021. 45 с.
  16. Шаповал И.Н. Россия в цифрах. 2021: Крат. стат. сб. Росстат. М., 2021. 275 с. https://rosstat.gov.ru/folder/13721.
  17. Резолюция по итогам IIКонгресса, посвященного Всемирному дню борьбы с ожирением. 28 февраля - 2 марта 2022 г. 5 с. worldobesitydayryssia.ru
  18. Bell M., Granath F, Martensson J., et al. KING (Karolinska Intensive care Nephrology Group). Cystatin C is correlated with mortality in patients with and without acute kidney injury. Nephrol. Dial. Transplant. 2009;24(10):3096- 102. doi: 10.1093/ndt/gfp196.
  19. Yndestad A., Landro L., Ueland T., et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur. Heart J. 2009;30(10):1229-36. Doi: 10.1093/ eurheartj/ehp088.
  20. Prins K.W, Thenappan T., Markowitz J.S., Pritzker M.R. Cardiorenal Syndrome Type 1: Renal Dysfunction in Acute Decompensated Heart Failure. J. Clin. Outcomes Manag. 2015;22(10):443-54. PMID: 27158218; PMCID: PMC4855293.
  21. Devarajan P. Neutrophil gelatinase-associated lipocalin-an emerging troponin for kidney injury. Nephrol. Dial. Transplant. 2008;23(12):3737-43. doi: 10.1093/ndt/gfn531.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies